Paper No. _____ Date Filed: May 4, 2015

Filed on behalf of:

INO Therapeutics LLC

By:

DOCKET

Dominick A. Conde dconde@fchs.com (212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Praxair Distribution, Inc. Petitioner, v.

INO Therapeutics LLC Patent Owner.

Case IPR2015-00524 U.S. Patent No. 8,293,284

PRELIMINARY RESPONSE BY PATENT OWNERS PURSUANT TO 37 C.F.R. § 42.107

TABLE OF CONTENTS

I.	INTE	RODUCTION1
II.	BAC	KGROUND
	A.	The Development of the '284 Patent
		1. The Initial INOT22 Protocol Was Carefully Constructed and Reviewed, and Did Not Contain the Claimed Exclusion Criteria
		 Unanticipated Serious Adverse Events Initially Occurred During the INOT22 Study
		 Based on the Unexpected Serious Adverse Events Early in the Trial, the INOT22 Protocol Was Amended and the Rate of SAEs Was Significantly Reduced
	B.	The '284 Prosecution History11
		1. The PTO Considered Many References
		2. Praxair Relies on the Same Statements Ikaria Overcame During Prosecution
	C.	The '284 Patent Claims
III.	PER	SON OF ORDINARY SKILL
IV.	CLA	IM CONSTRUCTION
V.	LEG	AL STANDARD
VI.	MOT AND OR H	XILLED ARTISAN WOULD NOT HAVE BEEN TVATED TO EXCLUDE NEONATES HAVING LVD NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING REASONABLY EXPECT THOSE NEONATES WOULD 'E EXPERIENCED SAES

		ventricular dysfunction in neonates is much different than in adults	28
	В.	A skilled artisan would not have reasonably expected that the claimed excluded neonates would have SAEs as initially occurred in the INOT22 Study	31
VII.	REV BERN	UND 1: THE BOARD SHOULD NOT INSTITUTE IEW BASED ON ALLEGED OBVIOUSNESS OVER VASCONI IN COMBINATION WITH INOMAX [®] LABEL, AND GOYAL	34
	A.	Praxiar fails to show that <i>Bernasconi</i> , the <i>INOmax</i> [®] <i>label</i> , <i>Loh</i> or <i>Goyal</i> include the claimed exclusion criteria	35
	B.	Praxair's Assertions that warnings in the art are applicable to the claimed exclusion criteria are unsupported	43
	C.	Praxair fails to raise any new arguments or supplement the record to address issues overcome during prosecution	46
	D.	Praxair fails to show that elements in dependent claims 5, 11, 20 and 28 are present in the prior art	49
VIII.	REV BERN	UND 2: THE BOARD SHOULD NOT INSTITUTE IEW BASED ON ALLEGED OBVIOUSNESS OVER VASCONI IN COMBINATION WITH INOMAX [®] LABEL, , GOYAL AND MACRAE	50
IX.	REV ICHL	UND 3: THE BOARD SHOULD NOT INSTITUTE IEW BASED ON ALLEGED OBVIOUSNESS OVER <i>NOSE</i> IN COMBINATION WITH <i>NEONATAL GROUP</i> , <i>RAE, LOH, GOYAL</i> AND <i>GERMANN</i>	52
X.	LIKE	XAIR FAILS TO DEMONSTRATE A REASONABLE ELIHOOD OF SUCCESS TO COUNTER THE ECTIVE EVIDENCE OF UNEXPECTED RESULTS	54
XI.	Conc	lusion	56

TABLE OF AUTHORITIES

Cases

Apple, Inc. v. ITC, 725 F.3d 1356 (Fed. Cir. 2013)
Ashland Oil, Inc. v. Delta Resins & Refractories, Inc., 776 F.2d 281 (Fed. Cir. 1985)44
CCS Fitness, Inc. v. Brunswick Corp., 288 F.3d 1359 (Fed. Cir. 2002)
<i>Graham v. John Deere Co.</i> , 383 U.S. 1 (1966)
<i>In re Cuozzo Speed Tech. LLC</i> , No. 14-1301, slip. op. (Fed. Cir. 2015)
<i>In re Dembiczak</i> , 175 F.3d 994 (Fed. Cir. 1999)24
<i>Insite Vision Inc., et al. v. Sandoz, Inc.,</i> 2014-1065 (Fed. Cir. 2015)
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007)
Leo Pharmaceutical Products, Ltd v. Rea, 726 F.3d 1346 (Fed. Cir. 2013)
<i>Phillips v. AWH Corp.</i> , 415 F.3d 1303 (Fed. Cir. 2005)21
<i>Rohm and Haas Co. v. Brotech Corp.</i> , 127 F.3d 1089 (Fed. Cir. 1997)44
Statutes
35 U.S.C. § 103 22, 23, 34, 50, 52
35 U.S.C. § 314(a)
35 U.S.C. § 325(d)

Regulations

37 C.F.R. § 42.1(b)	48
37 C.F.R. § 42.100(b)	20
37 C.F.R. § 42.104(b)(4)	24, 40
37 C.F.R. § 42.108(c)	.2, 22
37 C.F.R. § 42.6	58
37 C.F.R. § 42.65(a)	44
P.T.A.B.	
Int'l Securities Exchange, LLC v. Chicago Board Options Exchanges, Inc., IPR2014-00099, Paper 12 (P.T.A.B. May 22, 2014)	24, 40
Integrated Global Concepts, Inc., v. Advanced Messaging Tech., Inc., IPR2014-01027, Paper 16 (P.T.A.B. Dec. 22, 2014)	25, 56
Merial v. Virbac, IPR No. 2014-01279, Paper 13 (P.T.A.B. Jan. 22, 2015) 4, 25, 46, 4	48, 56
Mylan v. Gilead Sciences, Inc., IPR No. 2014-00888, Paper 15 (P.T.A.B. Dec. 9, 2014)	.4, 25
Mylan Pharma. Inc. v. Gilead Sciences, Inc., IPR No. 2014-00885, Paper 15 (P.T.A.B. Dec. 9, 2014)	44
Zetec, Inc. v. Westinghouse Elec. Co., LLC, IPR No. 2014-00384, Paper 10 (P.T.A.B. Jul. 23, 2014)	24, 40

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.